iMaps Capital Markets expands product portfolio with actively managed certificate for AI trading strategy
Liechtenstein, May 19, 2022 – iMaps Capital Markets (iMaps), a brand of the European structured products issuer iMaps ETI AG, in cooperation with Aiternativ Ltd. launched a new exchange-traded investment product: the Aiternativ Dynamic ETI (ISIN: DE000A3GW617). This exchange-traded instrument uses artificial intelligence in the form of a trading algorithm to control the underlying assets in order to generate reliable returns in the forex markets. It has recently been traded on the Stuttgart Stock Exchange and is approved for public distribution in Germany, Liechtenstein, Luxembourg, Spain, Portugal and Austria.
The investment strategy represented by this innovative certificate is based on the total return approach and thus aims to always achieve positive returns with limited risk and to secure the profits already made. Investments are made exclusively in contracts for difference (CFDs), i.e. derivative products, on the foreign exchange market (FOREX). The strategy is based on an automated trading system that identifies, evaluates and, if necessary, trades in short-term volatility breakouts. Aiternative Ltd. developed this system based on strict risk management principles.
In the underlying asset of the actively managed ETI, currencies and contracts for difference can be used for both appreciation (long positions) and depreciation (short positions) assumptions. As a result, it enables extensive flexibility and a return that is independent of the general stock and bond markets.
“I am pleased that we can now add another thematic exchange traded product to our portfolio, which is based on active currency management. Since the currency markets hardly correlate with classic shares and bonds, interesting diversification effects arise,” explains Andreas Woelfl, founder and Chairman of iMaps ETI AG. "The automated investment solution controlled by artificial intelligence, in combination with the total return approach, ensures reliable returns on the foreign exchange markets with a moderate risk profile."
“We are delighted to be listed on the Stuttgart Stock Exchange in partnership with iMaps Capital Markets. This is an important milestone for our company and a great step to build on our long-term vision to become a leading provider of artificial intelligence based trading systems,” said Hugo Malhoa, Head of Business Development at Aiternativ Ltd.
About iMaps ETI AG
iMaps ETI AG is an issuer of Exchange Traded Products (ETP) in the Principality of Liechtenstein with a focus on asset manager certificates in the form of Actively Managed Certificates.
iMaps Capital Markets focuses on providing asset managers with the platform for issuing Exchange Traded Instruments (ETI) as a white label solution in order to map the respective investment strategy. The spectrum represents both ETIs on classic investments such as shares, derivatives and funds, as well as on digital assets as an underlying. As a subgroup of Exchange Traded Products, they are an interesting, rapidly growing and cost-effective alternative to funds. Thanks to the approved securities prospectus of iMaps ETI AG, there is also the possibility of publicly offering ETIs to private investors.
For more information, visit: www.imaps-capital.com
About Aiternative
Aiternative Ltd. is a Swiss investment advisor to A.R. Suisse Financial GmbH.
Aiternativ's system uses a sophisticated automated trading tool that offers a range of investment opportunities that help investors capitalize on the power of compound interest. An important part of the system works through high-frequency, low-volume (HFLV) transactions. This means that while there are potentially hundreds of opportunities for a successful trade over the lifetime of the investment, only a tiny percentage of the account is used for the trades with the highest probability of success.
With the help of big data, AI and machine learning, historical performance data from numerous data points can be used effectively to better predict future price fluctuations and automatically react to them more effectively.
For more information, visit: www.aiternativ.com.
Contact:
public imaging GmbHGoldbekplatz 3, 22303 HamburgCharlotte Brigitte Looß /
Isabella von Köckritz
Tel.: +49 (0) 40 401999-292 / - 22
E-Mail: imaps@publicimaging.de
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom
